TACSTD2 and breast carcinoma: For instance, Sacituzumab govitecan against Trop2 was approved in breast cancer (BRCA), but also high expression levels of the TAA can be found in non-transformed tissue like head and neck epithelium (HNSC-normal) (Figure 1).